The US FDA has authorized Zyn nicotine pouches to make health claims that they lower the risk of six diseases compared to cigarettes. The approval arrived seven weeks after the Trump administration removed the previous FDA commissioner, who had opposed approving flavored nicotine products due to concerns about their appeal to young users.
Zyn pouches are small bags of nicotine that users place between their gum and lip. They come in flavors like mint and cinnamon and contain no tobacco. The new FDA authorization allows the manufacturer to tell smokers that using Zyn instead of cigarettes reduces the risk of mouth cancer, throat cancer, lung cancer, heart disease, stroke, and chronic obstructive pulmonary disease. This is the first time the FDA has permitted such health claims on a nicotine pouch product.
The timing of this decision has raised questions about regulatory independence. The former FDA commissioner had actively blocked approvals of flavored nicotine products, citing evidence that flavored options are more attractive to teenagers and can serve as a gateway to nicotine addiction. Seven weeks before this approval, the Trump administration removed this commissioner and replaced leadership at the agency. No official statement linked the two events, but the sequence has drawn scrutiny from public health advocates.
Nicotine pouches have grown rapidly in the US market, particularly among young people. Unlike cigarettes, they produce no smoke and leave no ash, making them easier to use discreetly at school or in public spaces. Health experts are divided on whether these products are genuinely less harmful than cigarettes or simply a different way to deliver an addictive drug to new users. The FDA’s claim authorization assumes users switch completely from cigarettes to Zyn, but research on what actually happens when pouches enter a market remains limited.
The health claims now permitted by the FDA apply only to adults who currently smoke and want to switch to a less harmful product. The agency has set conditions that Zyn cannot advertise these claims to non-smokers or young people. However, advertising restrictions are difficult to enforce on social media, where flavored nicotine products have already built a following among teenagers.
Public health organizations have expressed concern that the authorization came without sufficient evidence of long-term safety and without adequate safeguards against youth uptake. The decision reflects a broader tension in US tobacco regulation: whether to allow manufacturers to promote less harmful alternatives to cigarettes, or to restrict nicotine products that could create new addiction pathways. The FDA’s choice signals which priority it has chosen under current leadership.
Source: https://easternherald.com/2026/07/02/fda-zyn-nicotine-pouches-modified-risk-claim
